Role of interleukin-10 in the regulation of tumorigenicity of a T cell lymphoma

References

• Vieira P, de Waal-Malefyt R, Dang MN, . Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci USA 1991;88:1172–1176.
   PubMed Web of Science ®Google Scholar
• Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse helper T cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989;170:2081–2095.
   PubMed Web of Science ®Google Scholar
• Moore KW, de Waal Malefyt R, Coffman RL, . Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;19:683–765.
   PubMed Web of Science ®Google Scholar
• deWaal Malefyt R, Haanen J, Spits H, . IL-10 and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II MHC expression. J Exp Med 1991;174: 915–924.
   PubMed Web of Science ®Google Scholar
• Fiorentino DF, Zlotnik A, Vieira P, . IL-10 acts on the antigen presenting cell to inhibit cytokine production by TH1 cells. J Immunol 1991;146:3444–3451.
   PubMed Web of Science ®Google Scholar
• Ding L, Shevach EM. IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function. J Immunol 1992;148:3133–3139.
   PubMed Web of Science ®Google Scholar
• Hsu DH, Moore KW, Spits H. Differential effects of interleukin-4 and -10 on interleukin-2-induced interferon-g synthesis and lymphokine-activated killer activity. Int Immunol 1992;4:563–569.
   PubMed Web of Science ®Google Scholar
• Oswald IP, Gazzinelli RT, Sher A, . IL-10 synergizes with IL-4 and TGF-beta to inhibit macrophage cytotoxic activity. J Immunol 1992;148:3578–3582.
   PubMed Web of Science ®Google Scholar
• Ralph P, Nakoinz I, Sampson-Johannes A, . IL-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. J Immunol 1992;148:808–814.
   PubMed Web of Science ®Google Scholar
• Murphy EE, Terres G, Macatonia SE, . B7 and interleukin-12 cooperate for proliferation and IFN γ production by mouse Th1 clones that are unresponsive to B7 costimulation. J Exp Med 1994;80:223–231.
   Web of Science ®Google Scholar
• D’Andrea A, Aste AM, Valiante NM, . Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993;178:1041–1048.
   PubMed Web of Science ®Google Scholar
• Gruber MF, Williams CC, Gerrard TL. Macrophage-colony-stimulating factor expression by anti-CD45 stimulated human monocytes is transcriptionally up-regulated by IL-1 beta and inhibited by IL-4 and IL-10. J Immunol 1994;152:1354–1361.
   PubMed Web of Science ®Google Scholar
• Kopydlowski KM, Salkowski CA, Cody MJ, . Regulation of macrophage chemokine expression by lipopolysaccharide in vitro and in vivo. J Immunol 1999;163:1537–1544.
   PubMed Web of Science ®Google Scholar
• Hart PH, Hunt EK, Bonder CS, . Regulation of surface and soluble TNF receptor expression on human monocytes and synovial fluid macrophages by IL-4 and IL-10. J Immunol 1996; 157:3672–3680.
   PubMed Web of Science ®Google Scholar
• Gray D, Gray M. What are regulatory B cells?Eur J Immunol 2010;40:2677–2679.
   PubMed Web of Science ®Google Scholar
• Roncarolo MG, Gregori S, Battaglia M, . Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006;212:28–50.
   PubMed Web of Science ®Google Scholar
• Kühn R, Löhler J, Rennick D, . Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993;75:263–274.
   PubMed Web of Science ®Google Scholar
• Berg DJ, Davidson N, Kühn R, . Enterocolitis and colon cancer in interleukin- 10-deficient mice are associated with aberrant cytokine production and CD4+ TH1-like responses. J Clin Invest 1996;98: 1010–1020.
   PubMed Web of Science ®Google Scholar
• Rennick DM, Fort MM. Lessons from genetically engineered animal models XII. IL-10-deficient (IL-10-/-) mice and intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 2000;278: 829–833.
   PubMed Web of Science ®Google Scholar
• Singh B, Read S, Asseman C, . Control of intestinal inflammation by regulatory T cells. Immunol Rev 2001;182:190–200.
   PubMed Web of Science ®Google Scholar
• Eruslanov E, Kaliberov S, Daurkin I, . Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor infiltrated CD11b myeloid cells: a mechanism for immune evasion in cancer. J Immunol 2009;182:7548–7557.
   PubMed Web of Science ®Google Scholar
• Ikeguchi M, Hatada T, Yamamoto M, . Serum interleukin-6 and -10 levels in patients with gastric cancer. Gastric Cancer 2009;12: 95–100.
   PubMed Web of Science ®Google Scholar
• Chau GY, Wu CW, Lui WY, . Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann Surg 2000;231:552–528.
   PubMed Web of Science ®Google Scholar
• Salazar-Onfray F, López MN, Mendoza-Naranjo A. Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev 2007;18:171–182.
   PubMed Web of Science ®Google Scholar
• Sharma S, Stolina M, Lin Y, . T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J Immunol 1999;163:5020–5028.
   PubMed Web of Science ®Google Scholar
• Qin Z, Noffz G, Mohaupt M, . Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J Immunol 1997;159:770–776.
   PubMed Web of Science ®Google Scholar
• Halak BK, Maguire HC Jr, Lattime EC. Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res 1999;59:911–917.
   PubMed Web of Science ®Google Scholar
• Silini G, Maruyama Y. Studies of the LSA ascites lymphoma of C57BL mice. I. Transplantation characteristics and radiosensitivity of cells during serial passage. J. Natl Cancer Inst 1965;35:841–849.
   PubMed Web of Science ®Google Scholar
• Nagarkatti M, Toney DM, Nagarkatti PS. Immunomodulation by various nitrosoureas and its effect on the survival of the murine host bearing a syngeneic tumor. Cancer Res 1989;49:6587–6592.
   PubMed Web of Science ®Google Scholar
• Nagarkatti M, Clary SR, Nagarkatti PS. Characterization of tumor-infiltrating CD4+ T cells as Th1 cells based on lymphokine secretion and functional properties. J Immunol 1990;144:4898–4905.
   PubMed Web of Science ®Google Scholar
• Weiss B, Davidkova G, Zhou L-W. Antisense RNA gene therapy for studying and modulating biological processes. Cell Mol Life Sci 1999;55:334–358.
   PubMed Web of Science ®Google Scholar
• Nagarkatti M, Hassuneh M, Seth A, . Constitutive activation of the interleukin-2 gene in the induction of spontaneous in vitro transformation and tumorigenicity of T cells. Proc Natl Acad Sci USA 1994;91:7638–7642.
   PubMed Web of Science ®Google Scholar
• de Waal Malefyt R, Yssel H, de Vries JE. Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J Immunol 1993;150:4754–4765.
   PubMed Web of Science ®Google Scholar
• Hassuneh MR, Nagarkatti PS, Nagarkatti M. Evidence for the participation of IL-2 and IL-4 in the regulation of autonomous growth and tumorigenesis of transformed cells of lymphoid origin. Blood 1997;89:610–620.
   PubMed Web of Science ®Google Scholar
• Hammond-McKibben DM, Seth A, Nagarkatti PS, . Characterization of factors regulating successful immunotherapy using a tumor-specific cytotoxic T lymphocyte clone:role of interleukin-2, cycling pattern of lytic activity and adhesion molecules. Int J Cancer 1995;16;60:828–836.
   Web of Science ®Google Scholar
• Nagarkatti M, Kaplan AM. The role of suppressor T cells in BCNU-mediated rejection of a syngeneic tumor. J Immunol 1985;135: 1510–1517.
   PubMed Web of Science ®Google Scholar
• Matsuda M, Salazar F, Petersson M, . Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 1994;180:2371–2376.
   PubMed Web of Science ®Google Scholar
• Salazar-Onfray F, Petersson M, Franksson L, . IL-10 converts mouse lymphoma cells to a CTL-resistant, NK- sensitive phenotype with low but peptide-inducible MHC class I expression. J Immunol 1995;154:6291–6298.
   PubMed Web of Science ®Google Scholar
• Rohrer JW, Coggin JH. CD8 T cell clones inhibit antitumor T cell function by secreting IL-10. J Immunol 1995;155:5719–5727.
   PubMed Web of Science ®Google Scholar
• Wang L, Goillot E, Tepper RI. IL-10 inhibits alloreactive cytotoxic T lymphocyte generation in vivo. Cell Immunol 1994;159:152–169.
   PubMed Web of Science ®Google Scholar
• Trotta R, Col JD, Yu J, . TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J Immunol 2008;181: 3784–3792.
   PubMed Web of Science ®Google Scholar
• Gays F, Martin K, Kenefeck R, . Multiple cytokines regulate the NK gene complex-encoded receptor repertoire of mature NK cells and T cells. J Immunol 2005;175:2938–2947.
   PubMed Web of Science ®Google Scholar
• Llanes-Fernández L, Arango-Prado MC, Alcocer-González JM, . Association between the expression of IL-10 and T cell activation proteins loss in early breast cancer patients. J Cancer Res Clin Oncol 2009;135:255–264.
   PubMed Web of Science ®Google Scholar
• Inagaki A, Ishida T, Ishii T, . Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: high interleukin-5 and -10 levels are significant unfavorable prognostic factors. Int J Cancer 2006;118:3054–3061.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Estey E, Wen S, . The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer 2008;113:1605–1613.
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Fong T, Shabe P, . Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest 2001;19:239–247.
   PubMed Web of Science ®Google Scholar
• Ohara M, Yamaguchi Y, Matsuura K, . Possible involvement of regulatory T cells in tumor onset and progression in primary breast cancer. Cancer Immunol Immunother 2009;58:441–447.
   PubMed Web of Science ®Google Scholar
• Dummer W, Bastian BC, Ernst N, . Interleukin-10 production in malignant melanoma: preferential detection of IL-10-secreting tumor cells in metastatic lesions. Int J Cancer 1996;29;66:607–610.
   Web of Science ®Google Scholar
• Giovarelli M, Musiani P, Modesti A, . Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J Immunol 1995;155:3112–3123.
   PubMed Web of Science ®Google Scholar
• Richter G, Krüger-Krasagakes S, Hein G, . Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration. Cancer Res 1993;15;53:4134–4137
   Web of Science ®Google Scholar
• Zeytun A, Hassuneh M, Nagarkatti M, . Fas-Fas ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes: a lethal two way street. Blood 1997;90:1952–1959.
   PubMed Web of Science ®Google Scholar
• Zeytun A, Nagarkatti M, Nagarkatti PS. Growth of FasL-bearing tumor cells in syngeneic murine host induces apoptosis and toxicity in Fas(+) organs. Blood 2000;95:2111–2117.
   PubMed Web of Science ®Google Scholar